<DOC>
	<DOCNO>NCT02157831</DOCNO>
	<brief_summary>Patients clinical benefit follow single infusion CP-870 , 893 Protocol UPCC 10903 receive single repeat infusion CP-870,893 dose give UPCC 10903 intravenously .</brief_summary>
	<brief_title>Redosing With CP-870 , 893 Patients With Clinical Benefit After Single Infusion From A Phase I , Open-Label , Dose-Escalation Study CP-870,893 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Clinical benefit , include stable disease , partial response , complete response , without doselimiting toxicity single infusion CP870,893 ; however , patient experience transient , serious , fully reversible grade 13 increase ALT AST one dose CP870,893 may , otherwise eligible , receive second dose protocol . Age least 18 year old ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 ; Adequate bone marrow function document within 2 week prior treatment , define : White blood cell ( WBC ) count &gt; 3000 cells/μL without growth factor support ; Absolute neutrophil count ( ANC ) ≥1500/μL without growth factor support ; Platelets &gt; 100,000/μL without growth factor support ; Hemoglobin ≥10 g/dL . Adequate renal hepatic function document within 2 week prior treatment , define : Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 × ULN ; Creatinine clearance ( CLcr , measure calculate ) &gt; 80 mL/min ; Life expectancy least 12 week ; Signed write informed consent . Exclusion Criteria Concurrent treatment anticancer agent ; History autoimmune disorder , include pemphigus vulgaris , systemic mastocytosis , systemic lupus erythamatosus , dermatomyositis/polymyositis , rheumatoid arthritis , systemic sclerosis , Sjörgen 's syndrome , vasculitis/arteritis , Behcet 's syndrome , inflammatory bowel disease , autoimmune thyroiditis , multiple sclerosis , chronic inflammatory disease ; Treatment cancer therapy time first dose CP870,893 , except noted Section 4.4 ; 1 Cancer Therapy Evaluation Program , Common Terminology Criteria Adverse Events , Version 3.0 , DCTD , NCI , NIH , DHHS . 31 Mar 2003 ( http : //ctep.cancer.gov ) . History congestive heart failure , stroke , myocardial infarction ; Hereditary acquire coagulopathies ( e.g . hemophilia , von Willebrand 's disease , cancerassociated DIC ) ; Brain metastasis . Patient reproductive potential use effective method birth control pregnant breastfeed positive ( urine serum ) pregnancy test baseline ; Known sensitivity immunomodulating agent monoclonal antibody ; Alcohol abuse illicit drug use within 12 month enrollment ; History serum creatinine ≥2 mg/dL duration reason ; Urine dipstick 1+ positive blood ( menstruate female ) 2+ positive protein ; Positive HAHA antibody titer response treatment first dose CP870,893 ( determine Pfizer ) Clinically significant presence granular cellular cast centrifuge urine sediment ; Renal carcinoma renal metastasis ; Partial complete nephrectomy ; History dialysis ( peritoneal hemodialysis ) ; Prior treatment Amphotericin B cisplatin ; History insulindependent diabetes great 5 year ; Concomitant treatment systemic corticosteroid treatment systemic corticosteroid within 4 week baseline ; Concomitant treatment anticoagulant , coumadin heparin , except maintain patency indwell catheter ; Prior allergic reaction attribute compound similar chemical biologic composition study drug ( e.g. , rituximab immunoglobulin G ) ; Ongoing active infection ; Required use systemic antibiotic antifungal ongoing recurrent infection . Topical use antibiotic antifungal allow ; Other uncontrolled concurrent illness would preclude study participation ; Psychiatric illness social situation would preclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Subjects Clinical Benefit After Single Infusion CP - 870 , 893</keyword>
</DOC>